-
Mashup Score: 43
Outcomes in patients with hormone receptor–positive metastatic breast cancer worsen after one or more lines of endocrine-based therapy. Trastuzumab deruxtecan has shown efficacy in patients with me…
Source: www.nejm.orgCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 43
Outcomes in patients with hormone receptor–positive metastatic breast cancer worsen after one or more lines of endocrine-based therapy. Trastuzumab deruxtecan has shown efficacy in patients with me…
Source: www.nejm.orgCategories: General Medicine News, General HCPsTweet-
Among patients with metastatic breast cancer with low HER2 expression, treatment with trastuzumab deruxtecan prolonged progression-free survival as compared with the physician’s choice of chemotherapy. Full DESTINY-Breast06 trial results: https://t.co/6ZeFARPtR7 #ESMO24 https://t.co/nadxfVju7T
-
-
Mashup Score: 44
Outcomes in patients with hormone receptor–positive metastatic breast cancer worsen after one or more lines of endocrine-based therapy. Trastuzumab deruxtecan has shown efficacy in patients with me…
Source: www.nejm.orgCategories: General Medicine News, General HCPsTweet-
Among patients with metastatic breast cancer with low HER2 expression, treatment with trastuzumab deruxtecan prolonged progression-free survival as compared with the physician’s choice of chemotherapy. Full DESTINY-Breast06 trial results: https://t.co/6ZeFARPtR7 #ESMO24 https://t.co/nadxfVju7T
-
-
Mashup Score: 4Nurses Are ‘Critical Partners’ in the Clinical Trial Process - 17 day(s) ago
As biomarkers continue to be explored in resectable melanoma, oncology nurses will play a crucial role in the clinical trial process.
Source: www.oncnursingnews.comCategories: General Medicine News, Oncologists1Tweet-
At #ESMO24, an expert from @MDAndersonNews discussed the role nurses and APPs play in the ongoing research of biomarker testing for melanoma. She named these professionals "critical partners" in cancer clinical trials. https://t.co/aFdBC9H2To https://t.co/p0CQZ10euA
-
-
Mashup Score: 240
In Western countries, the current standard of care for resectable gastric cancer is perioperative chemotherapy. Preoperative chemoradiotherapy has been considered, but data are limited regarding th…
Source: www.nejm.orgCategories: General Medicine News, General HCPsTweet-
TOPGEAR: In a trial comparing chemotherapy and preoperative chemoradiotherapy with perioperative chemotherapy in patients with resectable gastric or GE junction cancer, no significant difference in overall survival was noted. Full trial results: https://t.co/jxKervUdpR #ESMO24 https://t.co/l48NOPG6o2
-
-
Mashup Score: 0
Oncology nurses should inform patients about adverse events and the signs of interstitial lung disease before treating their breast cancer with T-DXd.
Source: www.oncnursingnews.comCategories: General Medicine News, NursingTweet-
In an interview at #ESMO24, @nlinmd discussed the importance of discussing adverse events and interstitial lung disease when treating patients with trastuzumab deruxtecan. https://t.co/hQCOmq2Vma
-
-
Mashup Score: 241Preoperative Chemoradiotherapy for Resectable Gastric Cancer | NEJM - 1 month(s) ago
In Western countries, the current standard of care for resectable gastric cancer is perioperative chemotherapy. Preoperative chemoradiotherapy has been considered, but data are limited regarding th…
Source: www.nejm.orgCategories: General Medicine News, General HCPsTweet-
TOPGEAR: In a trial comparing chemotherapy and preoperative chemoradiotherapy with perioperative chemotherapy in patients with resectable gastric or GE junction cancer, no significant difference in overall survival was noted. Full trial results: https://t.co/jxKervUdpR #ESMO24 https://t.co/l48NOPG6o2
-
-
Mashup Score: 241Preoperative Chemoradiotherapy for Resectable Gastric Cancer | NEJM - 1 month(s) ago
In Western countries, the current standard of care for resectable gastric cancer is perioperative chemotherapy. Preoperative chemoradiotherapy has been considered, but data are limited regarding th…
Source: www.nejm.orgCategories: General Medicine News, General HCPsTweet-
TOPGEAR: In a trial comparing chemotherapy and preoperative chemoradiotherapy with perioperative chemotherapy in patients with resectable gastric or GE junction cancer, no significant difference in overall survival was noted. Full trial results: https://t.co/jxKervUdpR #ESMO24 https://t.co/l48NOPG6o2
-
-
Mashup Score: 5ESMO 2024 Kidney Cancer Highlights - 1 month(s) ago
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to …
Source: www.youtube.comCategories: General Medicine News, Oncologists1Tweet-
Drs. Wenxin (Vincent) Xu (@VincentWenxinXu) and Toni Choueiri (@DrChoueiri) covered kidney cancer updates from #ESMO24 https://t.co/tU90AtvOaq
-
-
Mashup Score: 2ESMO 2024 Prostate Cancer Highlights - 1 month(s) ago
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need t…
Source: www.youtube.comCategories: General Medicine News, Oncologists1Tweet-
Drs. Wenxin (Vincent) Xu (@VincentWenxinXu) and Atish Choudhury (@AtishChoudhury) covered prostate cancer updates from #ESMO24 https://t.co/eGOnrP0HAm
-
Among patients with metastatic breast cancer with low HER2 expression, treatment with trastuzumab deruxtecan prolonged progression-free survival as compared with the physician’s choice of chemotherapy. Full DESTINY-Breast06 trial results: https://t.co/6ZeFARPtR7 #ESMO24 https://t.co/nadxfVju7T